Patient characteristics
. | Value . |
|---|---|
| No. patients | 74 |
| Median age, y (range) | 38 (29-65) |
| Median CD4 cell count/dL (range) | 161 (3-691) |
| Median HIV viral load, copies/dL (range)* | 67000 (0-750 000) |
| Sex, no.(%) | |
| Male | 60 (81) |
| Female | 14 (19) |
| Risk group for HIV infection, no.(%) | |
| Intravenous drug use | 26 (35) |
| Homosexual male | 22 (30) |
| Heterosexual contact | 21 (28) |
| Unknown | 5 (7) |
| Previous AIDS defining event, no. (%) | 8 (11) |
| Previous HAART, no. (%) | 42 (57) |
| Histology, no. (%) | |
| Large noncleaved cell | 48 (65) |
| Small noncleaved, Burkitt | 21 (28) |
| Immunoblastic | 3 (4) |
| Anaplastic large cell | 2 (3) |
| Stage, no. (%) | |
| 1-2 | 22 (30) |
| 3-4 | 52 (70) |
| Age-adjusted IPI, no. (%) | |
| Low risk (0 factors) | 8 (11) |
| Low-intermediate risk (1 factor) | 24 (32) |
| High-intermediate risk (2 factors) | 25 (34) |
| High risk (3 factors) | 17 (23) |
| No. patients with extranodal involvement (%) | 55 (74) |
| Site of extranodal involvement, no. (%) | |
| Gastrointestinal tract | 29 (39) |
| Lung | 9 (12) |
| Bone marrow | 9 (12) |
| Liver | 9 (12) |
| Spleen | 9 (12) |
. | Value . |
|---|---|
| No. patients | 74 |
| Median age, y (range) | 38 (29-65) |
| Median CD4 cell count/dL (range) | 161 (3-691) |
| Median HIV viral load, copies/dL (range)* | 67000 (0-750 000) |
| Sex, no.(%) | |
| Male | 60 (81) |
| Female | 14 (19) |
| Risk group for HIV infection, no.(%) | |
| Intravenous drug use | 26 (35) |
| Homosexual male | 22 (30) |
| Heterosexual contact | 21 (28) |
| Unknown | 5 (7) |
| Previous AIDS defining event, no. (%) | 8 (11) |
| Previous HAART, no. (%) | 42 (57) |
| Histology, no. (%) | |
| Large noncleaved cell | 48 (65) |
| Small noncleaved, Burkitt | 21 (28) |
| Immunoblastic | 3 (4) |
| Anaplastic large cell | 2 (3) |
| Stage, no. (%) | |
| 1-2 | 22 (30) |
| 3-4 | 52 (70) |
| Age-adjusted IPI, no. (%) | |
| Low risk (0 factors) | 8 (11) |
| Low-intermediate risk (1 factor) | 24 (32) |
| High-intermediate risk (2 factors) | 25 (34) |
| High risk (3 factors) | 17 (23) |
| No. patients with extranodal involvement (%) | 55 (74) |
| Site of extranodal involvement, no. (%) | |
| Gastrointestinal tract | 29 (39) |
| Lung | 9 (12) |
| Bone marrow | 9 (12) |
| Liver | 9 (12) |
| Spleen | 9 (12) |
Other disease sites included bone (6 patients), soft tissue (4 patients), Waldeyer ring (4 patients), gingiva/tongue (3 patients), meninges (3 patients), kidney (3 patients), skin (3 patients), pleura (3 patients), and adrenal gland (2 patients).
n = 67.